Log in

NASDAQ:SBBPStrongbridge Biopharma Stock Price, Forecast & News

$3.51
-0.15 (-4.10 %)
(As of 07/10/2020 04:00 PM ET)
Add
Compare
Today's Range
$3.48
Now: $3.51
$3.71
50-Day Range
$3.30
MA: $3.72
$4.40
52-Week Range
$1.43
Now: $3.51
$4.63
Volume206,200 shs
Average Volume381,226 shs
Market Capitalization$190.42 million
P/E RatioN/A
Dividend YieldN/A
Beta1.6
Strongbridge Biopharma plc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs. The company's commercial products include Keveyis, an oral carbonic anhydrase inhibitor for treating hyperkalemic, hypokalemic, and related variants of primary periodic paralysis in the United States; and Macrilen, an oral growth hormone secretagogue receptor agonist for use in the diagnosis of patients with adult growth hormone deficiency. Its clinical-stage product candidates are Recorlev, a cortisol synthesis inhibitor, which is in a Phase III clinical trial that is used for the treatment of endogenous Cushing's syndrome; and Veldoreotide, a somatostatin analog that completed Phase II clinical trial for the treatment of acromegaly. The company was formerly known as Cortendo plc and changed its name to Strongbridge Biopharma plc in September 2015. Strongbridge Biopharma plc was founded in 1996 and is based in Trevose, Pennsylvania.
Read More
Strongbridge Biopharma logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.47 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SBBP
CUSIPN/A
Phone610-254-9200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$21.71 million
Book Value$1.33 per share

Profitability

Net Income$-49,450,000.00
Net Margins-181.82%

Miscellaneous

Employees71
Market Cap$190.42 million
Next Earnings Date7/29/2020 (Estimated)
OptionableOptionable

Receive SBBP News and Ratings via Email

Sign-up to receive the latest news and ratings for SBBP and its competitors with MarketBeat's FREE daily newsletter.

Strongbridge Biopharma (NASDAQ:SBBP) Frequently Asked Questions

How has Strongbridge Biopharma's stock been impacted by COVID-19 (Coronavirus)?

Strongbridge Biopharma's stock was trading at $2.32 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, SBBP shares have increased by 51.3% and is now trading at $3.51. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Strongbridge Biopharma?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Strongbridge Biopharma in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Strongbridge Biopharma.

When is Strongbridge Biopharma's next earnings date?

Strongbridge Biopharma is scheduled to release its next quarterly earnings announcement on Wednesday, July 29th 2020. View our earnings forecast for Strongbridge Biopharma.

How were Strongbridge Biopharma's earnings last quarter?

Strongbridge Biopharma plc (NASDAQ:SBBP) posted its quarterly earnings results on Wednesday, May, 6th. The biotechnology company reported ($0.19) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.22) by $0.03. The biotechnology company had revenue of $6.67 million for the quarter, compared to analysts' expectations of $5.97 million. Strongbridge Biopharma had a negative return on equity of 57.46% and a negative net margin of 181.82%. View Strongbridge Biopharma's earnings history.

What guidance has Strongbridge Biopharma issued on next quarter's earnings?

Strongbridge Biopharma issued an update on its FY 2020 Pre-Market earnings guidance on Wednesday, May, 6th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $22-26 million, compared to the consensus revenue estimate of $26.06 million.

What price target have analysts set for SBBP?

5 equities research analysts have issued 12-month target prices for Strongbridge Biopharma's shares. Their forecasts range from $6.00 to $18.00. On average, they expect Strongbridge Biopharma's share price to reach $9.88 in the next twelve months. This suggests a possible upside of 181.3% from the stock's current price. View analysts' price targets for Strongbridge Biopharma.

Has Strongbridge Biopharma been receiving favorable news coverage?

News articles about SBBP stock have been trending extremely negative recently, InfoTrie Sentiment reports. The research group identifies positive and negative media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Strongbridge Biopharma earned a news impact score of -4.0 on InfoTrie's scale. They also assigned headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the next few days. View the latest news about Strongbridge Biopharma.

Are investors shorting Strongbridge Biopharma?

Strongbridge Biopharma saw a drop in short interest in June. As of June 15th, there was short interest totaling 387,800 shares, a drop of 21.6% from the May 31st total of 494,700 shares. Based on an average trading volume of 327,700 shares, the short-interest ratio is presently 1.2 days. Approximately 1.1% of the shares of the stock are sold short. View Strongbridge Biopharma's Current Options Chain.

Who are some of Strongbridge Biopharma's key competitors?

What other stocks do shareholders of Strongbridge Biopharma own?

Who are Strongbridge Biopharma's key executives?

Strongbridge Biopharma's management team includes the following people:
  • Mr. John H. Johnson, Exec. Chairman (Age 62, Pay $765.19k)
  • Mr. Robert Matthew Lutz, Chief Financial Officer (Age 51, Pay $543.13k)
  • Mr. Richard S. Kollender CPA, M.B.A., CPA, Chief Operating Officer (Age 51, Pay $50.04k)
  • Dr. Fredric Cohen, Chief Medical Officer (Age 55, Pay $593.89k)
  • Dr. Per Marin M.D., Ph.D., Founder and Sr. Clinical Advisor

What is Strongbridge Biopharma's stock symbol?

Strongbridge Biopharma trades on the NASDAQ under the ticker symbol "SBBP."

How do I buy shares of Strongbridge Biopharma?

Shares of SBBP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Strongbridge Biopharma's stock price today?

One share of SBBP stock can currently be purchased for approximately $3.51.

How big of a company is Strongbridge Biopharma?

Strongbridge Biopharma has a market capitalization of $190.42 million and generates $21.71 million in revenue each year. The biotechnology company earns $-49,450,000.00 in net income (profit) each year or ($1.10) on an earnings per share basis. Strongbridge Biopharma employs 71 workers across the globe.

What is Strongbridge Biopharma's official website?

The official website for Strongbridge Biopharma is www.strongbridgebio.com.

How can I contact Strongbridge Biopharma?

Strongbridge Biopharma's mailing address is 900 NORTHBROOK DRIVE SUITE 200, TREVOSE PA, 19053. The biotechnology company can be reached via phone at 610-254-9200 or via email at [email protected]

This page was last updated on 7/12/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.